Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance

M Rose, JT Burgess, K O'Byrne, DJ Richard… - Frontiers in cell and …, 2020 - frontiersin.org
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …

Poly (ADP-ribose) polymerase inhibition: past, present and future

NJ Curtin, C Szabo - Nature Reviews Drug Discovery, 2020 - nature.com
The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …

Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19

L Bowles, S Platton, N Yartey, M Dave… - … England Journal of …, 2020 - Mass Medical Soc
Prolonged aPTT in Patients with Covid-19 In this study, 20% of patients with Covid-19 had a
prolonged activated partial-thromboplastin time. In 90% of these cases, the cause was lupus …

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

MM Gounder, NP Agaram, SE Trabucco… - Nature …, 2022 - nature.com
There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

Pan-cancer landscape of homologous recombination deficiency

L Nguyen, J WM Martens, A Van Hoeck… - Nature …, 2020 - nature.com
Homologous recombination deficiency (HRD) results in impaired double strand break repair
and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar …

The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations

A Villani, S Davidson, N Kanwar, WW Lo, Y Li… - Nature Cancer, 2023 - nature.com
We conducted integrative somatic–germline analyses by deeply sequencing 864 cancer-
associated genes, complete genomes and transcriptomes for 300 mostly previously treated …

Single duplex DNA sequencing with CODEC detects mutations with high sensitivity

JH Bae, R Liu, E Roberts, E Nguyen, S Tabrizi… - Nature Genetics, 2023 - nature.com
Detecting mutations from single DNA molecules is crucial in many fields but challenging.
Next-generation sequencing (NGS) affords tremendous throughput but cannot directly …

Molecular profiling for precision cancer therapies

ER Malone, M Oliva, PJB Sabatini, TL Stockley… - Genome medicine, 2020 - Springer
The number of druggable tumor-specific molecular aberrations has grown substantially in
the past decade, with a significant survival benefit obtained from biomarker matching …

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

EY Rosen, HH Won, Y Zheng, E Cocco… - Nature …, 2022 - nature.com
The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-
driven cancers, and we sought to characterize the molecular determinants of response and …